NLTX Key Statistics, Chart & Performance
The current stock price of NLTX is 3.49 USD. In the past month the price increased by 4.18%. In the past year, price increased by 61.39%.
NLTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About NLTX
Company Profile
Neoleukin Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The firm is engaged in providing immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. The firm uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Its primarily focused on cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. The firm operates through the research and development of de novo protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. The firm's primary areas of focus are on oncology, inflammation, and autoimmunity. Its de novo protein design process uses a set of advanced computational algorithms and methods to design functional de novo proteins.
Company Info
NEOLEUKIN THERAPEUTICS INC
1616 Eastlake Ave E Ste 360
Seattle WASHINGTON 98102 US
CEO: Jonathan G. Drachman
Employees: 7
Phone: 12067322133
NEOLEUKIN THERAPEUTICS INC / NLTX FAQ
What does NEOLEUKIN THERAPEUTICS INC do?
Neoleukin Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The firm is engaged in providing immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. The firm uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Its primarily focused on cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. The firm operates through the research and development of de novo protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. The firm's primary areas of focus are on oncology, inflammation, and autoimmunity. Its de novo protein design process uses a set of advanced computational algorithms and methods to design functional de novo proteins.
What is the current price of NLTX stock?
The current stock price of NLTX is 3.49 USD. The price increased by 1.45% in the last trading session.
Does NEOLEUKIN THERAPEUTICS INC pay dividends?
NLTX does not pay a dividend.
What is the ChartMill rating of NEOLEUKIN THERAPEUTICS INC stock?
NLTX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is NEOLEUKIN THERAPEUTICS INC (NLTX) stock traded?
NLTX stock is listed on the Nasdaq exchange.
What sector and industry does NEOLEUKIN THERAPEUTICS INC belong to?
NEOLEUKIN THERAPEUTICS INC (NLTX) operates in the Health Care sector and the Biotechnology industry.
Is NEOLEUKIN THERAPEUTICS INC (NLTX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NLTX.
NLTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NLTX. When comparing the yearly performance of all stocks, NLTX is one of the better performing stocks in the market, outperforming 87.21% of all stocks.
NLTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NLTX. No worries on liquidiy or solvency for NLTX as it has an excellent financial health rating, but there are worries on the profitability.
NLTX Financial Highlights
Over the last trailing twelve months NLTX reported a non-GAAP Earnings per Share(EPS) of -5.2. The EPS decreased by -136.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.25% | ||
| ROE | -45.57% | ||
| Debt/Equity | 0 |
NLTX Forecast & Estimates
6 analysts have analysed NLTX and the average price target is 1.53 USD. This implies a price decrease of -56.16% is expected in the next year compared to the current price of 3.49.